Yeong J, Lum HYJ, Teo CB, Tan BKJ, Chan YH, Tay RYK, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25(4):741–50. https://doi.org/10.1007/s10120-022-01301-0.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33. https://doi.org/10.1016/S0140-6736(18)31257-1.

CAS  Article  PubMed  Google Scholar 

Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022;12(3):670–91. https://doi.org/10.1158/2159-8290.CD-21-0683.

CAS  Article  PubMed  Google Scholar 

Sundar R, Liu DH, Hutchins GG, Slaney HL, Silva AN, Oosting J, et al. Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut. 2021;70(10):1823–32. https://doi.org/10.1136/gutjnl-2020-320805.

CAS  Article  PubMed  Google Scholar 

Sundar R, Tan P. Genomic analyses and precision oncology in gastroesophageal cancer: forwards or backwards? Cancer Discov. 2018;8(1):14–6. https://doi.org/10.1158/2159-8290.CD-17-1295.

Article  PubMed  Google Scholar 

Lee JJY. ImmunoAtlas: ATLA-220323–1: Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy: report information [cited 2022 September 13]. Available from: https://www.immunoatlas.org/ATLA/220423-1/. Accessed 15 Sept 2022

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302–11. https://doi.org/10.1016/j.jtho.2018.05.013.

Article  PubMed  PubMed Central  Google Scholar 

Ahn S, Kim KM. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28–8 pharmDx assays for responses to immunotherapy. Mod Pathol. 2021;34(9):1719–27. https://doi.org/10.1038/s41379-021-00823-9.

CAS  Article  PubMed  Google Scholar